Portfolio companies news

04 January 2018

Epic Sciences To Present At The 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit

Epic Sciences, Inc. (Epic) announces that it is one of six companies chosen to present at the second annual CTIC Capital Cross-Border China-US Healthcare Investment Summit. The summit will take place on Sunday, January 7 at the Hyatt Regency in San Francisco. 

04 January 2018

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the successful completion of a Series E financing led by Invus. Additional investors in the financing include Domain Associates, Lumira Capital, Masters Capital Management, RMI Partners and the Georgia Research Alliance Venture Fund.  In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors.

13 December 2017

Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index

Marinus Pharmaceuticals, Inc.(Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to the NASDAQ Biotechnology Index^®, which will become effective prior to the open of U.S. markets Monday, December 18, 2017.

13 December 2017

Atlas Genetics Expands Executive Team, Appointing Marc Jones as Chief Operating Officer and Chief Financial Officer

Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced the appointment of industry veteran Marc Jones as Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”).

30 November 2017

Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel

Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for characterization of circulating tumor cells (CTCs) within a blood sample. 

28 November 2017

ReVision Optics’ Raindrop Near Vision Inlay Featured in Presentations and Instructional Sessions at the American Academy of Ophthalmology Annual Meeting

ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that its Raindrop® Near Vision Inlay for presbyopia was featured in multiple scientific presentations and instructional courses at the annual meeting of the American Academy of Ophthalmology (AAO) held November 11-14 in New Orleans. The presentations highlighted study data focusing on key attributes to improve clinical outcomes with the Raindrop procedure.

13 November 2017

Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, on Friday, November 10, 2017, during the Retina Subspecialty Day of the American Academy of Ophthalmology  2017 Annual Meeting in New Orleans Charles C. Wykoff presented preliminary results from an exploratory clinical trial of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide for suprachoroidal administration with and without intravitreally injected EYLEA® (aflibercept) for the treatment of diabetic macular edema.

08 November 2017

Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and nine months ended  September 30, 2017  and provided an update on its key development programs.

08 November 2017

Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results

Neothetics , Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the third quarter 2017. Research and development expenses for the third quarter of 2017 were approximately  $0.5 million , compared to  $1.0 million  for the same quarter in 2016. Research and development expenses for the nine months ended  September 30, 2017  were  $3.6 million , compared to  $5.7 million  for the same period in 2016. 

07 November 2017

Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.